Harvard Review of Psychiatry
September 8, 2026
Warwick M. Green, Sanket B. Raut, F. E. James et al.
There is a need for new effective treatment options for posttraumatic stress disorder (PTSD), as many people with PTSD do not fully recover despite current treatments. 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy (MDMA-AT) is emerging as a new treatment option. We assessed the current body of MDMA-AT evidence for effectiveness in treating PTSD, associated impairments, and...
Journal of Psychedelic Studies
May 17, 2025
Daria Dikovskaya, Bhargav Srinivasa Desikan, Joel Frohlich et al.
2 citations
Abstract Background and aims Altered states of consciousness (ASC) represent acute and marked deviations from normal waking consciousness. Investigations into ASC are significant to problems in medicine, science, and philosophy, including the structure of conscious experience. Here, we conducted a preliminary investigation into the structure of ASC while addressing the role of psychedelics,...
Frontiers in Neuroscience
2025
Martin Boese, Rina Berman, Kennett D. Radford et al.
5 citations
Ketamine, a multimodal dissociative anesthetic, is widely used as a trauma analgesic in emergency situations. Ketamine is also used to treat psychiatric disorders due to its broad application potential, including treatment-resistant major depression. However, its impacts on the development of post-traumatic stress disorder (PTSD) and its potential as a treatment for PTSD are controversial. PTSD...
Pharmacology & Therapeutics
November 1, 2022
Sanket B Raut, Padmaja A Marathe, Liza Van Eijk et al.
62 citations
Post-traumatic stress disorder (PTSD), characterized by abnormally persistent and distressing memories, is a chronic debilitating condition in need of new treatment options. Current treatment guidelines recommend psychotherapy as first line management with only two drugs, sertraline and paroxetine, approved by U.S. Food and Drug Administration (FDA) for treatment of PTSD. These drugs have...